Kindra is a technology company.
Kindra has raised $5.0M across 1 funding round.
Kindra has raised $5.0M in total across 1 funding round.
Kindra has raised $5.0M in total across 1 funding round.
Kindra's investors include Banana Capital, Bread and Butter Ventures, Emmeline Ventures, EQT Ventures, Felix Capital, Female Founders Fund, IA Capital Group, OMERS Ventures, Partech Ventures, Primary Venture Partners, Primetime Partners, Sweet Capital.
Kindra is a direct-to-consumer brand specializing in vaginal health and sexual wellness products designed to alleviate symptoms of menopause, postpartum recovery, and vulvovaginal dryness.[1][2][4] Its estrogen-free, clinically tested, vegan, and hypoallergenic lineup includes moisturizers, arousal gels, lubricants, and supplements, serving women experiencing hormonal changes throughout life stages, with products recommended by over 3,000 OB/GYNs, pelvic floor therapists, urologists, and primary physicians.[1][4] Formerly Pepper & Wits, Kindra operates from Santa Monica, California, with a lean team of under 50 employees and reported revenues between $1-10 million, reflecting steady growth in the women's health market.[1][3][4]
Kindra emerged in 2019 from M13's Launchpad venture studio in partnership with P&G Ventures, absorbing P&G's existing menopause brand Pepper & Wits (though some sources note an earlier establishment around 2014).[1][2][3] Co-founders HongJoo Sun (CEO, former CEO of period underwear brand Dear Kate), Whitney Gosden (Head of Marketing), and Austin Deng (Head of Product) leveraged P&G's expertise in health and beauty innovation alongside M13's DTC agility and investor network to launch the brand.[2] Products were developed by P&G Ventures' scientists, addressing long-ignored menopause symptoms like hot flashes, mood swings, and dryness, marking Kindra as the first company from this joint Launchpad initiative.[2]
Kindra rides the wave of digital health and women's wellness tech, capitalizing on growing awareness of menopause—a market long neglected despite affecting all women, with 75% facing vaginal or sexual health issues.[2][4] Its timing aligns with telemedicine expansions (e.g., competitors like Elektra Health) and DTC personalization in femtech, amplified by post-pandemic demand for at-home, non-hormonal solutions amid clinician shortages.[1] By partnering with venture studios like M13 and P&G Ventures, Kindra influences the ecosystem through accelerated scaling, patent innovation in gynecology, and community-building, helping normalize menopause care and bridging consumer products with medical endorsement in a sector seeing acquisitions like Gennev (2022) and Memora Health (2024).[1][2]
Kindra is poised for expansion in the booming femtech space, potentially deepening telemedicine integrations, international reach, or subscription models to sustain its $1-10M revenue trajectory amid rising menopause discourse.[1][4] Trends like AI-driven personalization and corporate wellness programs for employee menopause support will shape its path, evolving its influence from niche DTC relief to a broader platform blending products, education, and community.[2][4] As hormonal health gains mainstream traction, Kindra's science-backed, hormone-free edge positions it to lead symptom management innovation.
Kindra has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2021 | $5.0M Seed | Banana Capital, Bread and Butter Ventures, Emmeline Ventures, EQT Ventures, Felix Capital, Female Founders Fund, IA Capital Group, OMERS Ventures, Partech Ventures, Primary Venture Partners, Primetime Partners, Sweet Capital, Mark Casady, Susan Solinsky |